Perlite Nanoclay Nanopowder - Purity >99%, Aps 80-100nm | White Powder, Density 2.5-10.5 Lb/ft³, 6 Month Warranty

1 INR (Approx.)

500 INR (Approx.)

1 USD ($) (Approx.)

Nanoshel

Medicine Grade

Medicine Grade

Delhi

Port of Nhava Sheva

1 Per Week

2000 Per Month

Contact us for information regarding our sample policy

Contact us for information regarding our sample policy

North America, Eastern Europe, Western Europe, Africa, Central America, Middle East, South America, Asia, Australia

South America, Africa, Asia

Virginiamycin is a class of streptogramin-related depsipeptides isolated from the bacterium Streptomyces virginiae and other Streptomyces bacterial species. Used in agriculture, specifically in livestock, to accelerate the growth of the animals and to prevent and treat infections.

Letrozole is part of a new generation of highly selective aromatase inhibitors and is an artificially synthesized benzotriazole derivative. Letrozole inhibits aromatase to lower estrogen levels, thus preventing estrogen from stimulating tumor growth. Its in vivo activity is 150-250 times stronger than that of first generation aromatase inhibitor Amarante. As it is highly selective, it will not impact glucocorticoid, mineralocorticoid and thyroid functions; even at high dosages, it will not have any inhibiting effects on adrenal corticosteroid secretion, giving it a high treatment index. Letrozole has no latent toxicity towards any bodily systems and target organs, has no mutagenicity and carcinogenic effects, has minimal toxic side effects, is well-tolerated, and has stronger anticancer effects than other aromatase inhibitors and antiestrogen drugs. Letrozole is suitable for advanced breast cancer postmenopausal patients who have not responded to estrogen-suppressing treatment and for early breast cancer treatment. It is used to treat postmenopausal patients with advanced breast cancer and serves as a second-line treatment to follow unsuccessful antiestrogen treatment. Compared to the current standard Tamoxifen treatment, Letrozole can better prevent the risk of breast cancer recurrence.Side effects Randomized grouping studies have shown that daily oral ingestion of 2.5mg Letrozole leads to a 33% rate of drug-related negative reactions, a percentage much lower than AG groupaEURtms 46%. Negative reactions to Letrozole are mostly mild or moderate, consisting mostly of nausea (2-9%), headache (0-7%), bone pain (4-10%), hot flashes (0-9%) and weight gain (2-8%). Other uncommon side effects include constipation, diarrhea, itching, rash, joint pain, chest pain, abdominal pain, fatigue, insomnia, dizziness, edema, high blood pressure, arrhythmia, thrombosis, dyspnea, vaginal bleeding, etc.Chemical Properties white to light yellow crystalUses A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic